Oral iron use, by DOPPS country and cross-section |
N Ptnts | Wgtd % | Total N | ||
---|---|---|---|---|
DOPPS Country | DOPPS Cross-section | 996 | 11.0% | 9,117 |
All | DOPPS 2(2002) | |||
DOPPS 3(2006) | 937 | 11.0% | 8,552 | |
DOPPS 3(2007) | 897 | 11.5% | 7,672 | |
AusNZ | DOPPS 2(2002) | 58 | 11.6% | 513 |
DOPPS 3(2006) | 18 | 3.8% | 527 | |
DOPPS 3(2007) | 19 | 3.7% | 486 | |
Belgium | DOPPS 2(2002) | 125 | 23.3% | 538 |
DOPPS 3(2006) | 25 | 4.8% | 509 | |
DOPPS 3(2007) | 16 | 4.7% | 420 | |
Canada | DOPPS 2(2002) | 113 | 18.3% | 601 |
DOPPS 3(2006) | 128 | 24.7% | 551 | |
DOPPS 3(2007) | 103 | 23.1% | 445 | |
France | DOPPS 2(2002) | 26 | 4.9% | 528 |
DOPPS 3(2006) | 63 | 11.5% | 551 | |
DOPPS 3(2007) | 51 | 9.7% | 543 | |
Germany | DOPPS 2(2002) | 53 | 9.5% | 571 |
DOPPS 3(2006) | 31 | 5.1% | 583 | |
DOPPS 3(2007) | 28 | 4.4% | 623 | |
Italy | DOPPS 2(2002) | 10 | 1.7% | 576 |
DOPPS 3(2006) | 7 | 1.3% | 533 | |
DOPPS 3(2007) | 6 | 1.1% | 542 | |
Japan | DOPPS 2(2002) | 66 | 3.6% | 1,805 |
DOPPS 3(2006) | 506 | 27.4% | 1,832 | |
DOPPS 3(2007) | 531 | 28.5% | 1,867 | |
Spain | DOPPS 2(2002) | 32 | 5.2% | 613 |
DOPPS 3(2006) | 8 | 1.1% | 666 | |
DOPPS 3(2007) | 8 | 1.5% | 555 | |
Sweden | DOPPS 2(2002) | 247 | 45.4% | 547 |
DOPPS 3(2006) | 9 | 1.4% | 542 | |
DOPPS 3(2007) | 14 | 3.0% | 511 | |
UK | DOPPS 2(2002) | 32 | 5.9% | 565 |
DOPPS 3(2006) | 83 | 18.6% | 445 | |
DOPPS 3(2007) | 81 | 21.8% | 351 | |
US | DOPPS 2(2002) | 234 | 10.5% | 2,260 |
DOPPS 3(2006) | 59 | 3.5% | 1,813 | |
DOPPS 3(2007) | 40 | 3.2% | 1,329 |
Medications reported as prescribed (not necessarily taken) in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.